Segments

3 Months Ended

Mar. 31, 2014

Segment Reporting [Abstract]

SEGMENTS

SEGMENTS

We currently manage our operations in two reportable segments, pharmaceuticals and diagnostics. The pharmaceuticals segment consists of two operating segments, our (i) pharmaceutical research and development segment which is focused on the research and development of pharmaceutical products, and vaccines, and (ii) the pharmaceutical operations we acquired in Chile, Mexico, Israel, Spain, Brazil, and Uruguay. The diagnostics segment consists of two operating segments, our (i) pathology operations we acquired through the acquisition of OPKO Lab and (ii) point-of-care and molecular diagnostics operations. There are no inter-segment sales. We evaluate the performance of each segment based on operating profit or loss. There is no inter-segment allocation of interest expense and income taxes.

Information regarding our operations and assets for our operating segments and the unallocated corporate operations as well as geographic information are as follows:

	For the three months ended March 31,
(In thousands)	2014			2013
Product revenues:
Pharmaceuticals	$	19,828		$	15,527
Diagnostics	—			—
Corporate	—			—
	$	19,828		$	15,527
Revenue from services:
Pharmaceuticals	$	—		$	—
Diagnostics	1,910			3,052
Corporate	60			40
	$	1,970		$	3,092
Revenue from transfer of intellectual property:
Pharmaceuticals	$	285		$	12,500
Diagnostics	191			257
Corporate	—			—
	$	476		$	12,757
Operating (loss) income:
Pharmaceuticals	$	(16,573	)	$	8,483
Diagnostics	(7,078		)	(9,634		)
Corporate	(6,137		)	(5,025		)
Less: Operating loss attributable to noncontrolling interests	(489		)	(597		)
	$	(30,277	)	$	(6,773	)
Depreciation and amortization:
Pharmaceuticals	$	1,849		$	1,695
Diagnostics	1,691			1,689
Corporate	24			45
	$	3,564		$	3,429
Revenues:
United States	$	2,446		$	15,849
Chile	7,285			7,741
Spain	6,150			4,324
Israel	4,546			2,572
Mexico	1,831			890
Uruguay	16			—
	$	22,274		$	31,376

(In thousands)	March 31, 2014		December 31, 2013
Assets:
Pharmaceuticals	$	1,067,848	$	1,065,033
Diagnostics	113,515		116,944
Corporate	174,329		209,539
	$	1,355,692	$	1,391,516
Goodwill:
Pharmaceuticals	$	175,097	$	175,408
Diagnostics	50,965		50,965
Corporate	—		—
	$	226,062	$	226,373

During the three months ended March 31, 2014 and 2013, no customer represented more than 10% of our total revenue. As of March 31, 2014 and December 31, 2013, no customer represented more than 10% of our accounts receivable balance.